Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy.

Shin DH, Kwon GS.

Int J Pharm. 2017 Feb 25;518(1-2):307-311. doi: 10.1016/j.ijpharm.2017.01.006. Epub 2017 Jan 3.

PMID:
28062368
2.

d-3-Deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway.

Gradziel CS, Jordan PA, Jewel D, Dufort FJ, Miller SJ, Chiles TC, Roberts MF.

Biochim Biophys Acta. 2016 Nov;1861(11):1808-1815. doi: 10.1016/j.bbalip.2016.09.001. Epub 2016 Sep 4.

PMID:
27600289
3.

WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling.

Teng Y, Pi W, Wang Y, Cowell JK.

Oncogene. 2016 Sep 1;35(35):4633-40. doi: 10.1038/onc.2015.527. Epub 2016 Jan 25.

4.

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

Jhaveri K, Chandarlapaty S, Iyengar N, Morris PG, Corben AD, Patil S, Akram M, Towers R, Sakr RA, King TA, Norton L, Rosen N, Hudis C, Modi S.

Clin Breast Cancer. 2016 Aug;16(4):276-83. doi: 10.1016/j.clbc.2015.11.004. Epub 2015 Nov 19.

PMID:
26726007
5.

KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.

Liu W, Vielhauer GA, Holzbeierlein JM, Zhao H, Ghosh S, Brown D, Lee E, Blagg BS.

Mol Pharmacol. 2015 Jul;88(1):121-30. doi: 10.1124/mol.114.097303. Epub 2015 May 4.

6.

Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.

Desale SS, Raja SM, Kim JO, Mohapatra B, Soni KS, Luan H, Williams SH, Bielecki TA, Feng D, Storck M, Band V, Cohen SM, Band H, Bronich TK.

J Control Release. 2015 Jun 28;208:59-66. doi: 10.1016/j.jconrel.2015.02.001. Epub 2015 Feb 3.

7.

Heat shock protein 90 positively regulates Chikungunya virus replication by stabilizing viral non-structural protein nsP2 during infection.

Das I, Basantray I, Mamidi P, Nayak TK, B M P, Chattopadhyay S, Chattopadhyay S.

PLoS One. 2014 Jun 24;9(6):e100531. doi: 10.1371/journal.pone.0100531. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122906.

8.

Inhibition of cell growth by BrMC through inactivation of Akt in HER-2/neu-overexpressing breast cancer cells.

Cao XZ, Xiang HL, Quan MF, He LH.

Oncol Lett. 2014 May;7(5):1632-1638. Epub 2014 Feb 18.

9.

E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.

Samant RS, Clarke PA, Workman P.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):6834-9. doi: 10.1073/pnas.1322412111. Epub 2014 Apr 23.

10.

Heat shock protein 90 (hsp90) expression and breast cancer.

Zagouri F, Bournakis E, Koutsoukos K, Papadimitriou CA.

Pharmaceuticals (Basel). 2012 Sep 12;5(9):1008-20. doi: 10.3390/ph5091008.

11.

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.

Powers MV, Valenti M, Miranda S, Maloney A, Eccles SA, Thomas G, Clarke PA, Workman P.

Oncotarget. 2013 Nov;4(11):1963-75.

12.

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.

Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA.

Invest New Drugs. 2014 Feb;32(1):14-24. doi: 10.1007/s10637-013-9971-6. Epub 2013 May 18.

13.

LPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 in lung vascular endothelial cells and mouse lung.

Barabutis N, Handa V, Dimitropoulou C, Rafikov R, Snead C, Kumar S, Joshi A, Thangjam G, Fulton D, Black SM, Patel V, Catravas JD.

Am J Physiol Lung Cell Mol Physiol. 2013 Jun 15;304(12):L883-93. doi: 10.1152/ajplung.00419.2012. Epub 2013 Apr 12.

14.

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, Rodenas E, Hudis C, O'Shaughnessy J, Baselga J.

Breast Cancer Res Treat. 2013 May;139(1):107-13. doi: 10.1007/s10549-013-2510-5. Epub 2013 Apr 12.

15.

Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.

Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ.

Cell Death Dis. 2013 Mar 28;4:e566. doi: 10.1038/cddis.2013.101.

16.

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.

Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC.

J Immunol. 2013 Feb 1;190(3):1360-71. doi: 10.4049/jimmunol.1200593. Epub 2013 Jan 4.

17.

HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells.

Newman B, Liu Y, Lee HF, Sun D, Wang Y.

Cancer Res. 2012 Sep 1;72(17):4551-61. doi: 10.1158/0008-5472.CAN-11-3600. Epub 2012 Jun 29.

18.

Inhibition of Cell Growth and Induction of Apoptosis by Antrodia camphorata in HER-2/neu-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2/neu, and Disruption of the PI3K/Akt Signaling Pathway.

Lee CC, Yang HL, Way TD, Kumar KJ, Juan YC, Cho HJ, Lin KY, Hsu LS, Chen SC, Hseu YC.

Evid Based Complement Alternat Med. 2012;2012:702857. doi: 10.1155/2012/702857. Epub 2012 Jun 3.

19.

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer.

Wong AL, Lee SC.

Int J Breast Cancer. 2012;2012:415170. doi: 10.1155/2012/415170. Epub 2012 May 9.

20.

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.

Rodrigues LM, Chung YL, Al Saffar NM, Sharp SY, Jackson LE, Banerji U, Stubbs M, Leach MO, Griffiths JR, Workman P.

BMC Res Notes. 2012 May 23;5:250. doi: 10.1186/1756-0500-5-250.

Supplemental Content

Support Center